1SB
SABS icon

1ST Source Bank’s SAB Biotherapeutics SABS Stock Holding History

1ST Source Bank’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$6.88K – 256
2023
Q4 		$6.88K Hold
1,000
– – ﹤0.01% 250
2023
Q3 		$6.3K Hold
1,000
– – ﹤0.01% 244
2023
Q2 		$8.3K Hold
1,000
– – ﹤0.01% 244
2023
Q1 		$4.4K Hold
1,000
– – ﹤0.01% 249
2022
Q4 		$5.9K Hold
1,000
– – ﹤0.01% 245
2022
Q3 		$7K Hold
1,000
– – ﹤0.01% 237
2022
Q2 		$15K Buy
+1,000
New +$21K ﹤0.01% 245

Other funds holding SABS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

1ST Source Bank's SABS Position: Q1 2024 in Review

1ST Source Bank sold out of SAB Biotherapeutics (SABS) in Q1 2024, closing a stake of 1,000 shares — an estimated $6.88K sold.

1ST Source Bank first reported a position in SABS in Q2 2022 and held it in 7 quarters. The position peaked at $15K in Q2 2022. 24 funds tracked by Wall St. Rank hold SABS as of Q1 2024.

  • 1ST Source Bank reported no remaining SAB Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • 1ST Source Bank sold 1,000 SAB Biotherapeutics shares in Q1 2024, an estimated $6.88K.
  • 1ST Source Bank first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 7 quarters.
  • 1ST Source Bank's SAB Biotherapeutics position peaked at $15K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2024.

Based on 1ST Source Bank's 13F filing for Q1 2024, filed 9 May 2024.